Competitive Polymerase Chain Reaction for the Quantification of N-myc Gene Copy Number in Neuroblastoma

Tumor Biology ◽  
1996 ◽  
Vol 17 (5) ◽  
pp. 262-270 ◽  
Author(s):  
Akira Inoue ◽  
Ziaul Hasan ◽  
Hiromichi Hemmi ◽  
Naotoshi Kanda ◽  
Yasuhide Hayashi ◽  
...  
1997 ◽  
Vol 85 (2) ◽  
pp. 161-169 ◽  
Author(s):  
Ric Price ◽  
Grant Robinson ◽  
Alan Brockman ◽  
Alan Cowman ◽  
Sanjeev Krishna

1992 ◽  
Vol 200 (1) ◽  
pp. 1-6 ◽  
Author(s):  
M. Volkenandt ◽  
A. P. Dicker ◽  
D. Banerjee ◽  
R. Fanin ◽  
B. Schweitzer ◽  
...  

2009 ◽  
Vol 389 (1) ◽  
pp. 74-76 ◽  
Author(s):  
Luis J. Leandro-García ◽  
Susanna Leskelä ◽  
Cristina Montero-Conde ◽  
Iñigo Landa ◽  
Elena López-Jimenez ◽  
...  

1994 ◽  
Vol 40 (4) ◽  
pp. 630-636 ◽  
Author(s):  
R Sestini ◽  
C Orlando ◽  
L Zentilin ◽  
S Gelmini ◽  
P Pinzani ◽  
...  

Abstract We present an original application of competitive polymerase chain reaction (PCR) for measuring oncogene amplification in DNA from human tumors by simultaneous PCR amplification of genomic DNA with fixed amounts of an internal standard (competitor DNA). Competitors share the same sequence as the target genes but contain an additional 15- to 20-base-pair insert, which allows resolution of the amplified products after polyacrylamide gel electrophoresis and ethidium bromide staining. The gene copy number is derived from the ratio between the intensities of the bands corresponding to the amplified products. Using this procedure, we measured c-erbB-2 amplification in breast and bladder carcinomas in both fresh tumor tissues and paraffin-embedded tissue samples and assessed the precision, sensitivity, and accuracy of the assay. Competitive PCR is a simple, reliable, and accurate method for the evaluation of c-erbB-2 amplification and is potentially suitable for use in the clinical laboratory.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Young-Ho Kim ◽  
Eunyoung Emily Lee ◽  
Hye-Won Sim ◽  
Eun-Kyung Kang ◽  
Yoon-Ho Won ◽  
...  

AbstractThe correlation between copy number variation (CNV) and the susceptibility to systemic lupus erythematosus (SLE) has been reported for various immunity-related genes. However, the contribution of CNVs to SLE susceptibility awaits more investigation. To evaluate the copy numbers in immunity-related genes such as TNFAIP3, TNIP1, IL12B, TBX21 (T-bet), TLR7, C4A, C4B, CCL3L1, and CCL3L3, the modified real competitive polymerase chain reaction (mrcPCR) assay was employed, and the association between the copy numbers and SLE susceptibility was analyzed in 334 SLE patients and 338 controls. CCL3L3-null status was significantly associated with SLE susceptibility (OR > 18, P < 0.0001), which remained significant by Bonferroni’s correction (corrected P = 0.0007). However, the significant association between C4B low-copy status and SLE susceptibility (OR = 1.6051, P = 0.0331) became non-significant by Bonferroni’s correction (corrected P = 0.3938). Except for these results, no other significant association between SLE susceptibility and copy number status in other genes was observed. The CCL3L3-null status may be a significant factor for SLE susceptibility.


1999 ◽  
Vol 20 (2) ◽  
pp. 230 ◽  
Author(s):  
Marianne Jorgensen ◽  
Maja Bévort ◽  
Thuri S. Kledal ◽  
Brian V. Hansen ◽  
Marlene Dalgaard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document